Biphenotypic sinonasal sarcoma: An expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression

Lisa M. Rooper, Shih Chiang Huang, Cristina R. Antonescu, William H. Westra, Justin A. Bishop

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Summary Biphenotypic sinonasal sarcoma (BSNS) is a recently recognized low-grade sarcoma that exhibits both neural and myogenic differentiation. This unique dual phenotype stems from recurrent rearrangements in PAX3, a transcription factor that promotes commitment along both lineages. While identification of PAX3 rearrangements by fluorescence in situ hybridization (FISH) can confirm a BSNS diagnosis, this assay is not widely available. This study evaluates whether an expanded immunohistochemical panel can facilitate recognition of BSNS without molecular analysis. Eleven cases of BSNS were identified from the surgical pathology archives of two academic medical centers. In 8 cases, the diagnosis was confirmed by FISH using custom probes for PAX3. In 3 cases, FISH failed but histologic and immunophenotypic findings were diagnostic for BSNS. All 11 BSNS (100%) were at least focally positive for S100 as well as calponin and/or smooth muscle actin. In addition, 10 (91%) of 11 expressed nuclear β-catenin, 8 (80%) of 10 expressed factor XIIIa, 4 (36%) of 11 expressed desmin, and 3 (30%) of 10 expressed myogenin. All 11 tumors were negative for SOX10. While no single marker resolves immunohistochemical overlap between BSNS and its histologic mimickers such as nerve sheath tumors, an extended immunohistochemical panel that includes β-catenin and SOX10 helps to support the diagnosis of BSNS without the need for gene rearrangement studies.

Original languageEnglish (US)
Pages (from-to)44-50
Number of pages7
JournalHuman Pathology
Volume55
DOIs
StatePublished - Sep 1 2016

Fingerprint

Catenins
Sarcoma
Fluorescence In Situ Hybridization
Factor XIIIa
Nerve Sheath Neoplasms
Myogenin
Surgical Pathology
Desmin
Gene Rearrangement
Smooth Muscle
Actins
Phenotype

Keywords

  • Biphenotypic sinonasal sarcoma
  • Immunohistochemistry
  • Sinonasal tract
  • SOX10
  • β-Catenin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Biphenotypic sinonasal sarcoma : An expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression. / Rooper, Lisa M.; Huang, Shih Chiang; Antonescu, Cristina R.; Westra, William H.; Bishop, Justin A.

In: Human Pathology, Vol. 55, 01.09.2016, p. 44-50.

Research output: Contribution to journalArticle

Rooper, Lisa M. ; Huang, Shih Chiang ; Antonescu, Cristina R. ; Westra, William H. ; Bishop, Justin A. / Biphenotypic sinonasal sarcoma : An expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression. In: Human Pathology. 2016 ; Vol. 55. pp. 44-50.
@article{7895c59dabd34757854125a7c19c5df6,
title = "Biphenotypic sinonasal sarcoma: An expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression",
abstract = "Summary Biphenotypic sinonasal sarcoma (BSNS) is a recently recognized low-grade sarcoma that exhibits both neural and myogenic differentiation. This unique dual phenotype stems from recurrent rearrangements in PAX3, a transcription factor that promotes commitment along both lineages. While identification of PAX3 rearrangements by fluorescence in situ hybridization (FISH) can confirm a BSNS diagnosis, this assay is not widely available. This study evaluates whether an expanded immunohistochemical panel can facilitate recognition of BSNS without molecular analysis. Eleven cases of BSNS were identified from the surgical pathology archives of two academic medical centers. In 8 cases, the diagnosis was confirmed by FISH using custom probes for PAX3. In 3 cases, FISH failed but histologic and immunophenotypic findings were diagnostic for BSNS. All 11 BSNS (100{\%}) were at least focally positive for S100 as well as calponin and/or smooth muscle actin. In addition, 10 (91{\%}) of 11 expressed nuclear β-catenin, 8 (80{\%}) of 10 expressed factor XIIIa, 4 (36{\%}) of 11 expressed desmin, and 3 (30{\%}) of 10 expressed myogenin. All 11 tumors were negative for SOX10. While no single marker resolves immunohistochemical overlap between BSNS and its histologic mimickers such as nerve sheath tumors, an extended immunohistochemical panel that includes β-catenin and SOX10 helps to support the diagnosis of BSNS without the need for gene rearrangement studies.",
keywords = "Biphenotypic sinonasal sarcoma, Immunohistochemistry, Sinonasal tract, SOX10, β-Catenin",
author = "Rooper, {Lisa M.} and Huang, {Shih Chiang} and Antonescu, {Cristina R.} and Westra, {William H.} and Bishop, {Justin A.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.humpath.2016.04.009",
language = "English (US)",
volume = "55",
pages = "44--50",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Biphenotypic sinonasal sarcoma

T2 - An expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression

AU - Rooper, Lisa M.

AU - Huang, Shih Chiang

AU - Antonescu, Cristina R.

AU - Westra, William H.

AU - Bishop, Justin A.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Summary Biphenotypic sinonasal sarcoma (BSNS) is a recently recognized low-grade sarcoma that exhibits both neural and myogenic differentiation. This unique dual phenotype stems from recurrent rearrangements in PAX3, a transcription factor that promotes commitment along both lineages. While identification of PAX3 rearrangements by fluorescence in situ hybridization (FISH) can confirm a BSNS diagnosis, this assay is not widely available. This study evaluates whether an expanded immunohistochemical panel can facilitate recognition of BSNS without molecular analysis. Eleven cases of BSNS were identified from the surgical pathology archives of two academic medical centers. In 8 cases, the diagnosis was confirmed by FISH using custom probes for PAX3. In 3 cases, FISH failed but histologic and immunophenotypic findings were diagnostic for BSNS. All 11 BSNS (100%) were at least focally positive for S100 as well as calponin and/or smooth muscle actin. In addition, 10 (91%) of 11 expressed nuclear β-catenin, 8 (80%) of 10 expressed factor XIIIa, 4 (36%) of 11 expressed desmin, and 3 (30%) of 10 expressed myogenin. All 11 tumors were negative for SOX10. While no single marker resolves immunohistochemical overlap between BSNS and its histologic mimickers such as nerve sheath tumors, an extended immunohistochemical panel that includes β-catenin and SOX10 helps to support the diagnosis of BSNS without the need for gene rearrangement studies.

AB - Summary Biphenotypic sinonasal sarcoma (BSNS) is a recently recognized low-grade sarcoma that exhibits both neural and myogenic differentiation. This unique dual phenotype stems from recurrent rearrangements in PAX3, a transcription factor that promotes commitment along both lineages. While identification of PAX3 rearrangements by fluorescence in situ hybridization (FISH) can confirm a BSNS diagnosis, this assay is not widely available. This study evaluates whether an expanded immunohistochemical panel can facilitate recognition of BSNS without molecular analysis. Eleven cases of BSNS were identified from the surgical pathology archives of two academic medical centers. In 8 cases, the diagnosis was confirmed by FISH using custom probes for PAX3. In 3 cases, FISH failed but histologic and immunophenotypic findings were diagnostic for BSNS. All 11 BSNS (100%) were at least focally positive for S100 as well as calponin and/or smooth muscle actin. In addition, 10 (91%) of 11 expressed nuclear β-catenin, 8 (80%) of 10 expressed factor XIIIa, 4 (36%) of 11 expressed desmin, and 3 (30%) of 10 expressed myogenin. All 11 tumors were negative for SOX10. While no single marker resolves immunohistochemical overlap between BSNS and its histologic mimickers such as nerve sheath tumors, an extended immunohistochemical panel that includes β-catenin and SOX10 helps to support the diagnosis of BSNS without the need for gene rearrangement studies.

KW - Biphenotypic sinonasal sarcoma

KW - Immunohistochemistry

KW - Sinonasal tract

KW - SOX10

KW - β-Catenin

UR - http://www.scopus.com/inward/record.url?scp=84975147702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975147702&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.04.009

DO - 10.1016/j.humpath.2016.04.009

M3 - Article

C2 - 27137987

AN - SCOPUS:84975147702

VL - 55

SP - 44

EP - 50

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -